Northland Capital 'Cautiously Optimistic' on Roll Out of EnteroMedics' (ETRM) VBLOC Therapy
Tweet Send to a Friend
Northland Capital affirms EnteroMedics (NASDAQ: ETRM) at Outperform with a price target of $7 following news that the company received ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
